SCHEMBL24329378

SCHEMBL24329378

COc1ccc2nc(NC(=O)c3ccn(C)n3)sc2c1

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NPC1 O15118 12/20 0.66
▸ RAB9A P51151 11/20 0.66
▸ SCD O00767 7/20 0.66
▸ KMT2A Q03164 6/20 0.66
▸ MEN1 O00255 5/20 0.66
▸ SMN1; SMN2 Q16637 5/20 0.64
▸ MAPT P10636 4/20 0.64
▸ TP53 P04637 3/20 0.64
▸ HTT P42858 2/20 0.64
▸ POLB P06746 2/20 0.64
▸ USP2 O75604 1/20 0.64
▸ CYP1A2 P05177 1/20 0.63
▸ CYP3A4 P08684 1/20 0.63
▸ CYP2C19 P33261 1/20 0.63
▸ DYRK1A Q13627 1/20 0.63
▸ CASP2 P42575 1/20 0.61
▸ KDM4E B2RXH2 4/20 0.60
▸ HPGD P15428 2/20 0.60
▸ ALDH1A1 P00352 1/20 0.60
▸ CASP1 P29466 1/20 0.60

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24329373 0.91 NPC1 (0.63) NPC1RAB9ASCDKMT2AMEN1
SCHEMBL26658545 0.81 NPC1 (0.67) NPC1RAB9ASCDKMT2AMEN1
SCHEMBL16681363 0.81 SCD (0.88) NPC1RAB9ASCDKMT2AMEN1
SCHEMBL31243 0.80 SCD (1.00) NPC1RAB9ASCDKMT2AMEN1
SCHEMBL30930 0.79 NPC1 (0.73) NPC1RAB9ASCDKMT2AMEN1
SCHEMBL30917 0.79 SCD (0.83) NPC1RAB9ASCDKMT2AMEN1
SCHEMBL13329411 0.79 NPC1 (0.71) NPC1RAB9ASCDKMT2AMEN1
SCHEMBL4918742 0.78 SCD (0.86) NPC1RAB9ASCDKMT2AMEN1
SCHEMBL26658231 0.78 DYRK1A (0.61) NPC1RAB9ASCDKMT2AMEN1
SCHEMBL26884209 0.78 NPC1 (0.51) NPC1RAB9ASCDKMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230382903-A1 SMALL MOLECULE MODULATORS OF GP130 SIGNALING PATHWAYS, TOPICAL FORMULATIONS AND METHOD OF USE THEREOF CARTHRONIX INC (US) 2023-11-30 — — US disclosed
US-20230382903-A1 SMALL MOLECULE MODULATORS OF GP130 SIGNALING PATHWAYS, TOPICAL FORMULATIONS AND METHOD OF USE THEREOF CARTHRONIX INC (US) 2023-11-30 — — US disclosed
WO-2022082071-A1 SMALL MOLECULE MODULATORS OF GP130 SIGNALING PATHWAYS, TOPICAL FORMULATIONS AND METHOD OF US THEREOF CARTHRONIX, INC. (US) 2022-04-21 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230382903-A1 SMALL MOLECULE MODULATORS OF GP130 SIGNALING PATHWAYS, TOPICAL FORMULATIONS AND METHOD OF USE THEREOF STAT1, STAT3, STAT6 NPC1 2133/4885RAB9A 3504/4885SCD 4653/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback